Introduction
The synthesis and deposition of ECM proteins is highly regulated and plays a critical role in tissue development, homeostasis, wound healing, and inflammation (1) (2) (3) . Overexpression of ECM proteins may lead to tissue fibrosis with severe impairment of organ function. A hallmark of fibrotic diseases such as pulmonary fibrosis, hepatic cirrhosis, progressive systemic sclerosis, and osteomyelofibrosis, is the pathological accumulation of the ECM proteins collagen type I and fibronectin (4) (5) (6) (7) . Receivedfor publication 17 May 1993 and in revisedform 26 July 1993.
Type I procollagen mRNA levels are increased in experimental and clinical fibrotic states (6, 8, 9) , which implies a regulation at the pretranslational level. Colocalization of members of the TGF-(3 family of growth and differentiation factors with ECM proteins in affected tissues (3, 8) and the stimulatory effect of TGF-3 on collagen and fibronectin steady state mRNA levels (3, 10) suggest an important role of these growth factors in tissue fibrosis. Collagen type I is a triple helical molecule composed of two al (I) and one a2(I) collagen gene products. Recent progress has lead to the identification ofimportant regulatory elements of the murine and human a 1(I) gene. Several binding sites for the GC box binding transcription factor Spl were located in the first intron of the human gene (11) , to which enhancer-like activities were ascribed ( 12) . In addition, two highly conserved GC box elements were functionally characterized in the promoter of the murine al (I) gene ( 13) . Both elements also contain an overlapping CCAAT box motif and function individually as mutually exclusive binding sites for the transcription factors NF-I (CCAAT box factor) and Spl (GC box factor) thereby creating a direct repeat of NF-I/Spl switch elements ( 14) . The two elements control the high basal activity of the murine a I(I) gene in fibroblasts ( 15) , which contain both high NF-I and Spl binding activity. In contrast, only very low amounts ofSpl binding activities can be detected in a normal liver where only minimal amounts of a 1(I) transcripts can be measured. Interestingly, this weak binding affinity of Spl to the a I(I) promoter was substantially increased and correlated with induced al (I) mRNA levels in different models of experimental liver fibrosis ( 16) .
Under the assumption that GC-rich elements play a crucial role in determining the transcriptional activity of the human a I (I) gene, we have examined the effect of the GC-binding antibiotic mithramycin (16, (18) (19) (20) on collagen gene regulation in human primary fibroblasts. Our results reveal that mithramycin inhibits Spl but not NF-I binding to the NF-I/ Spl switch elements in vitro.
At nontoxic doses, mithramycin selectively decreases basal a I(I) collagen gene transcription and inhibits TGF-13I induction of a I (I) mRNA levels in human primary fibroblasts. This indicates that although the activity ofthe collagen-al (I) gene is highly dependent on GC-rich regulatory elements, the activity of other genes, including the collagenase gene, is not. (27) , and the cDNA of rat fibronectin was provided by R. 0. Hynes (Massachusetts Institute of Technology, Cambridge, MA) (28).
Nuclear protein extraction. Nuclear proteins were extracted from cultured F 109 embryonic lung fibroblasts as previously described (15) .
DNAse I protection assay. The plasmid pUCI9-al (I) was digested with EcoRI (multiple cloning site 5' of basepair position -252) and SmaI (-17 bp) and the resulting fragment containing the al (I) promoter was gel purified and endlabeled by a fill in reaction at the EcoRI site with Klenow fragment of DNA polymerase I (Boehringer Mannheim GmbH, Mannheim, Germany) using [a 32P]dATP (3, 000 Ci/ mmol). Either nuclear FH109 protein extracts, BSA, or mithramycin were incubated with 30 kcpm/reaction of probe for 20 min on ice. DNAse I protection assays were further carried out essentially as described ( 15) .
Gel retardation assay. The FP2 oligonucleotide spanning the promoter sequences from -131 to -1 10 bp ( 15 ) 
Results
Collagen (I) and collagenase mRNA levels. Human FH109 primary fibroblast cells were exposed to the antibiotic mithramycin. As measures of toxicity, we assessed cell growth, morphology and viability ofFH 109 cells cultured in the presence of different concentrations of mithramycin over a period of 8 d. At concentrations of mithramycin ranging from 10 nM to 100 nM, cell growth and morphology were not altered as compared to untreated controls. A fivefold reduction in cell growth was observed when a mithramycin concentration of 1 ,uM was used, while cell morphology remained unchanged (data not shown). However, concentrations as high as 10 AM resulted in complete cell death after 4 d (Fig. 1) .
In the next set of experiments, total RNA was extracted Figure 3 . Northern blot analysis of total RNA from mithramycin and PMA-treated FH 109 fibroblasts. Cells were cultured at 70-80% confluency for the indicated time ( 1, 3, 6 , and 24 h) in control medium or in medium containing either a 10 nM concentration of mithramycin, a 100 nM concentration of PMA, or both drugs combined. The same filter was probed, stripped, and reprobed with the indicated radiolabeled cDNAs including a GAPDH cDNA. Shown are densitometric plots after normalization of fibronectin, collagen-a 1 (I), c-jun, and collagenase signals for GADPH. Signal intensities from unstimulated and uncultured cells were arbitrarily set 100%. a, Medium; o, mithramycin; m, PMA; a, mithramycin/PMA. basal and early PMA-induced c-jun mRNA levels were unaffected after 1 and 3 h of coincubation with mithramycin, but decreased below their respective control levels 6 and 24 h after mithramycin treatment. These data suggest that inhibition of the collagenase induction might be associated with a reduction of c-jun transcripts.
Preincubation of FH 109 cells with a 100 nM concentration of mithramycin for 24 h resulted in a complete inhibition of PMA-induced transcription ofthe collagenase gene after 1 and 8 h of treatment (Fig. 4) when compared to the corresponding controls. In this experiment, it was also shown that incubation with human TGF-# 1 at a 100 pM final concentration lead to a slight increase of a 1 (I) mRNA levels after 8 h in the absence of mithramycin, while a 24-h preincubation with mithramycin almost completely abolished this induction.
The mRNA levels of another important ECM protein in tissue fibrosis, fibronectin, were also tested (Fig. 3 ). While PMA alone shows a weak stimulatory effect after 24 h over control level, mithramycin decreased both basal and PMA-induced fibronectin mRNA levels (Fig. 3, lanes 13 and 15, respectively). Mithramycin had, however, no significant effect on the mRNA levels of the GAPDH housekeeping gene.
Mithramycin interferes with transcription factor binding.
The first 500-bp upstream of the start site of transcription of the human a 1 (I) collagen gene is highly GC-rich (> 60%), as compared to the human collagenase promoter (GC-bp content = 45%). Since mithramycin has a high affinity to GC-rich stretches of DNA, we determined mithramycin binding sites in the human a I(I) promoter by DNAse I protection assays, alongside the footprints mediated by nuclear proteins from untreated FH109 cells (Fig. 5) . This assay reveals a concentration-dependent binding of mithramycin (Fig. 5, lanes 2-4) to all GC-rich regions of the a I (I) promoter that are also protected from DNAse I digest by the nuclear fibroblast extracts (Fig. 5 , lanes 5 and 6, and schematic drawing). This result suggested the possibility that mithramycin might interfere with transcription factor binding to the collagen-a 1(I) promoter. Additional information on this possible interference of mithramycin with transcription factor binding was sought in gel retardation assays (Fig. 6 ). For this purpose, the FP2 (footprint 2) oligonucleotide, which contains an complete NF-I/ Sp I switch element and spans from basepairs -130 to -1 10 of the a1(I) promoter, was prepared as a radiolabeled probe. While no FP2-probe was retarded in the absence of nuclear extract (Fig. 6, lane I) , both Sp I and NF-I transcription factor binding activities were present in the FH 109 protein extracts. The identity of both factors was tested in competition experiments using oligonucleotides with high affinity consensus binding sites for either factor ([15 ] , and data not shown). Additionally, the nuclear extracts were coincubated with mithramycin ranging from 10 nM to 10 ,qM final concentration (Fig. 6, lanes  3-7, respectively) . At 10 tiM, mithramycin competed with the binding of Spl and increased NF-I binding to the FP2 probe (Fig. 6, lane 7) . FH 109 cells that were incubated with mithramycin at 1 nM, 100 nM, and 10 ,uM final concentrations were harvested after 3 h. Radiolabeled run on transcripts were prepared and hybridized to filter-bound cDNA probes. Fig. 7 al (I) gene activity by 60%. In contrast, the transcription ofthe collagenase, a 1(111) collagen, and GAPDH genes remained unaltered. Only at 10 gM were all genes affected, which again indicates a toxic effect of mithramycin at this concentration (see Fig. 1 ).
Discussion
The promoter of the a I(I) collagen gene is highly active in collagen-producing fibroblasts ( 13) and mainly regulated by the interaction ofthe transcription factors NF-I and Sp I with a tandem repeat of NF-I/Sp switch elements ( 14, 15 Our in vitro analysis demonstrates that the GC-binding antibiotic mithramycin binds to regulatory elements of the human a I(I) collagen promoter, which inhibits Spl and increases NF-I binding to the NF-I/Spl switch elements. Recent functional studies on the isolated NF-I/Sp switch elements demonstrated that the ratio ofthe binding activities rather than the absolute concentrations ofthe two transcription factors determine a 1 (I) promoter activity ( 14) . The present results suggest a similar function of these elements in the intact a I (I) gene. Competition with SpI and increased NF-I binding by mithramycin leads to a substantial decrease of a 1 (I) gene transcription and reduced levels of a I (I) mRNA in human fibroblasts. This implies further that Sp might be crucial for the maintainance of the high transcriptional activity of the collagen gene in human fibroblasts. These conclusions substantiate a possible significant role of increased Sp binding activities during the state ofenhanced collagen production in experimental fibrogenesis ( 16) . Previous studies have demonstrated that an enhanced activity of Sp can result from protein-protein interactions of Sp 1 bound to the promoter with Sp I bound to more distal sites (34) . Additionally, high transcriptional activity of the SV40 enhancer required the binding of Spl to the SV40 early promoter (35) . Although a collagen-a I(I) enhancer element has not been unequivocally identified, enhancer-like activities were ascribed to the first intron of the a I (I) gene ( 12) , which contains functional Sp 1 binding sites ( 1 1, 36) . Interestingly, synergistic interactions between collagen-a 1 (I) intron and promoter sequences were reported recently (37, 38 ) and could explain the different activities of Sp I bound to the isolated promoter or to the promoter in the intact gene. The potential of mithramycin to disrupt protein/protein interactions of distal factors by interfering with the binding of Sp 1 to GC-rich regulatory elements of the a 1 (I) promoter could be a valuable tool in disclosing the mechanisms ofexperimental fibrogenesis.
Mithramycin reduces fibronectin mRNA levels, which are also upregulated in tissue fibrogenesis. This effect could only be explained when further insight into the regulation of this gene has been obtained. Similarly, the mechanisms how TGF-f upregulates the a I(I) gene are not well understood but are required to understand how mithramycin blocks this induction. Since TGF-3 is thought to be involved in the development of many forms of tissue fibrosis, it will be interesting to examine in more detail how mithramycin interferes with its activity. Our data further demonstrate that the basal transcription of the collagenase gene is unchanged at nontoxic concentrations of mithramycin. Therefore, it is possible to change the balance between ECM deposition and degradation. This could have a therapeutic impact in an already established fibrotic state.
Mithramycin interferes with the intracellular signaling pathway through protein kinase C, resulting in an inhibition of enhanced collagenase transcription by PMA. Since collagenase activation is mediated by the formation of an APl transcription factor complex (33), the observed inhibition of basal and PMA-induced c-jun transcription by mithramycin could explain the effects. Mithramycin can inhibit the expression of many genes perhaps by interfering with Sp I binding to regulatory elements (17) (18) (19) . This might explain the narrow therapeutic range ofthis drug when used clinically (20) . To increase its therapeutic range mithramycin might be modified so that the specificity ofits DNA binding can be directed to crucial and highly unique regulatory element in the target gene (39) . An interesting target for such a designed sequence specific DNA binding drug might be the NF-I/Spl switch elements of the collagen-a 1(I) gene.
